Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' influenza vaccine GSK2186877A · 1 trial · 1 indication
The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)
| Arm | Type | Description |
|---|---|---|
| New generation influenza vaccine GSK2186877A Group | EXPERIMENTAL | Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0 |
| Fluarix elderly Group | ACTIVE_COMPARATOR | Subjects aged \>= 65 years receiving 1 dose of Fluarix vaccine at Day 0 |
| Fluarix young Group | ACTIVE_COMPARATOR | Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0 |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' influenza vaccine GSK2186877A | BIOLOGICAL | One intramuscular injection at Day 0 |
| GSK Biologicals' Fluarix | BIOLOGICAL | One intramuscular injection at Day 0 |
Inclusion Criteria: All subjects must satisfy the following criteria at study entry: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subje...
GSK2186877A is an investigational influenza vaccine developed by GSK Biologicals. It is being studied for the prevention of influenza in adults, with a completed Phase 3 clinical trial that enrolled 192 participants aged 65 years or older.
GSK2186877A is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is being developed by GSK Biologicals, the vaccines division of GSK.
GSK2186877A is in Phase 3 clinical development. A Phase 3 trial, NCT00765076, has been completed. The vaccine is investigational and has not been approved for use; it remains in clinical development.
GSK2186877A has one completed Phase 3 clinical trial, NCT00765076, titled 'Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older.' The trial was conducted in the United States and Spain, enrolled 192 participants, and was randomized, double-blind, and active-controlled.
GSK2186877A is a vaccine designed to stimulate the immune system to produce a protective response against influenza. As a vaccine, it works by exposing the immune system to influenza antigens, prompting the body to develop immunity against the virus.